C. difficile Testing
Revogene provides healthcare systems an opportunity to minimize the overall burden of C. difficile through improved care and efficiency.
Catalog Number: 410300
Improve Efficiency, Deliver Standardization
- Improve overall lab efficiency with Revogene’s simplified sample prep and 2 minutes hands-on-time.
- Molecular accuracy using real-time PCR technology allows laboratories to deliver actionable results for improved decision making and appropriate management of patients suspected of having a CDI.
“The system is very easy to work with, I was able to start and run an experiment after only 5 minutes of training!”
Senior technician molecular diagnostics
Support & Documents
Colonization is more common than C. diff infection. The patient exhibits NO clinical symptoms (asymptomatic) but may test positive for the C.diff organism or its toxin gene. With infection, the patient exhibits clinical symptoms and tests positive for the C.diff organism and/or its toxin.
Use a stool toxin test as part of a multi-step algorithm (ie, glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test [NAAT]; or NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no pre-agreed institutional criteria for patient stool submission.
Use a NAAT alone or a multi-step algorithm for testing (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a toxin test alone when there are pre-agreed institutional criteria for patient stool submission.
There is insufficient data to recommend the use of biologic markers as an adjunct to diagnosis.
Revogene C. difficile – 87493
Ready to get a handle on C. difficile testing? Let’s talk